Published in Pediatr Infect Dis J on September 01, 1999
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun (2000) 2.84
Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine. Infect Immun (2002) 2.25
Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol (2006) 2.20
Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun (2001) 1.74
Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev (2006) 1.53
Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol (2009) 1.38
Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev (2012) 1.31
Pneumococcal carriage in children in The Netherlands: a molecular epidemiological study. J Clin Microbiol (2001) 1.29
Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun (2005) 1.21
Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. Clin Vaccine Immunol (2007) 1.16
The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM conjugate vaccine. Immunology (2006) 1.14
Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J (2014) 1.12
Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine. Vaccine (2009) 1.10
Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol (2008) 1.10
Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197. Infect Immun (2002) 1.07
A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med (2014) 1.07
Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr Infect Dis J (2010) 1.05
CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect Immun (2000) 1.05
Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother (2013) 1.03
Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect Immun (2007) 1.01
New pneumococcal vaccines for children. Arch Dis Child (2001) 0.99
Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice. Infect Immun (2002) 0.99
Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol (2007) 0.97
Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine (2010) 0.94
Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. Virulence (2013) 0.91
Childhood pyogenic meningitis: clinical and investigative indicators of etiology and outcome. J Natl Med Assoc (2007) 0.90
Emergence of penicillin-nonsusceptible Streptococcus pneumoniae invasive clones in Canada. J Clin Microbiol (2002) 0.90
Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis. Open Biol (2013) 0.90
Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model. Infect Immun (2003) 0.89
Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun (2010) 0.89
Protein carriers of conjugate vaccines: characteristics, development, and clinical trials. Hum Vaccin Immunother (2013) 0.89
The lack of Pneumococcal surface protein C (PspC) increases the susceptibility of Streptococcus pneumoniae to the killing by microglia. Med Microbiol Immunol (2005) 0.88
The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity. Pediatr Infect Dis J (2014) 0.88
Serotypes and sequence types of pneumococci causing invasive disease in Scotland prior to the introduction of pneumococcal conjugate polysaccharide vaccines. J Clin Microbiol (2004) 0.87
Genetic variation influences the B-cell response to immunization with a pneumococcal polysaccharide conjugate vaccine. Infect Immun (2003) 0.87
Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bull World Health Organ (2008) 0.87
Antibiotic-resistant invasive pediatric Streptococcus pneumoniae clones in Israel. J Clin Microbiol (2003) 0.87
Prevention of Pneumococcal Meningitis. Curr Infect Dis Rep (2002) 0.84
Antigen processing of the heptavalent pneumococcal conjugate vaccine carrier protein CRM(197) differs depending on the serotype of the attached polysaccharide. Infect Immun (2003) 0.84
Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol (2012) 0.84
Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine. Clin Diagn Lab Immunol (2005) 0.83
In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant. Cytokine (2016) 0.80
Outer membrane protein complex of Meningococcus enhances the antipolysaccharide antibody response to pneumococcal polysaccharide-CRM₁₉₇ conjugate vaccine. Clin Vaccine Immunol (2011) 0.79
What can children gain from pneumococcal conjugate vaccines? Eur J Pediatr (2004) 0.77
Diverse evolutionary patterns of pneumococcal antigens identified by pangenome-wide immunological screening. Proc Natl Acad Sci U S A (2017) 0.76
Sugar-Protein Connectivity Impacts on the Immunogenicity of Site-Selective Salmonella O-Antigen Glycoconjugate Vaccines. Angew Chem Int Ed Engl (2015) 0.76
Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice. Infect Immun (2005) 0.75
Transformation of intact yeast cells treated with alkali cations. J Bacteriol (1983) 100.26
The complete atomic structure of the large ribosomal subunit at 2.4 A resolution. Science (2000) 28.25
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology (1998) 26.77
The structural basis of ribosome activity in peptide bond synthesis. Science (2000) 18.82
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J (2000) 11.94
Classification of primary progressive aphasia and its variants. Neurology (2011) 11.82
Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med (2001) 10.56
Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med (2000) 6.83
Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. Arch Fam Med (2000) 6.62
Climate impact of increasing atmospheric carbon dioxide. Science (1981) 5.67
Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis (2000) 5.52
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med (1999) 5.50
Detailed analysis of the mouse H-2Kb promoter: enhancer-like sequences and their role in the regulation of class I gene expression. Cell (1986) 5.39
Molecular bases of dominant negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J (1990) 5.08
The adverse impact of heavy episodic drinkers on other college students. J Stud Alcohol (1995) 4.34
The assessment of binge eating severity among obese persons. Addict Behav (1982) 4.02
Pupil-led sex education in England (RIPPLE study): cluster-randomised intervention trial. Lancet (2004) 3.86
A common positive trans-acting factor binds to enhancer sequences in the promoters of mouse H-2 and beta 2-microglobulin genes. Proc Natl Acad Sci U S A (1987) 3.80
A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immunol (2001) 3.74
Interferon response sequence potentiates activity of an enhancer in the promoter region of a mouse H-2 gene. Nature (1986) 3.73
Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis (1999) 3.72
Vitamin E supplementation and in vivo immune response in healthy elderly subjects. A randomized controlled trial. JAMA (1997) 3.68
Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene. J Biol Chem (1997) 3.66
Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med (2011) 3.63
Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med (1998) 3.62
Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol (1995) 3.45
Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet (2000) 3.42
Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. Genes Dev (1989) 3.29
Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol (1991) 3.21
Placement of protein and RNA structures into a 5 A-resolution map of the 50S ribosomal subunit. Nature (1999) 3.20
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics (1998) 3.13
Climate response times: dependence on climate sensitivity and ocean mixing. Science (1985) 3.09
Parvovirus genome: nucleotide sequence of H-1 and mapping of its genes by hybrid-arrested translation. J Virol (1983) 3.00
The emerging role of the emergency care practitioner. Emerg Med J (2004) 2.95
Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol (2008) 2.85
Antigenic and phenotypic variations of Haemophilus influenzae type b lipopolysaccharide and their relationship to virulence. Infect Immun (1986) 2.84
A minor high-molecular-weight outer membrane protein of Haemophilus influenzae type b is a protective antigen. Infect Immun (1985) 2.81
Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol (1987) 2.79
The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis (2000) 2.79
The dominant W42 spotting phenotype results from a missense mutation in the c-kit receptor kinase. Science (1990) 2.75
An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods (1990) 2.72
Rapid nonradioactive detection of the major cystic fibrosis mutation. Am J Hum Genet (1990) 2.72
Prenatal and postnatal prevalence of Turner's syndrome: a registry study. BMJ (1996) 2.65
A multistate outbreak of Salmonella enterica Serotype Newport infection linked to mango consumption: impact of water-dip disinfestation technology. Clin Infect Dis (2003) 2.57
Giant Rashba-type spin splitting in bulk BiTeI. Nat Mater (2011) 2.49
Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry (1997) 2.49
Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J (1991) 2.47
Identification of a gene conferring resistance to zinc and cadmium ions in the yeast Saccharomyces cerevisiae. Mol Gen Genet (1989) 2.46
Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation. J Exp Med (1998) 2.40
Influence of Growth Conditions on the Production of a Bacteriocin, Pediocin AcH, by Pediococcus acidilactici H. Appl Environ Microbiol (1991) 2.38
An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A (2001) 2.28
A transmembrane relationship between fibronectin and vinculin (130 kd protein): serum modulation in normal and transformed hamster fibroblasts. Cell (1981) 2.26
Variation in practice for discretionary admissions. Impact on estimates of quality of hospital care. JAMA (1994) 2.24
Metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke. J Natl Cancer Inst (2001) 2.24
Morbidity in Turner syndrome. J Clin Epidemiol (1998) 2.23
Inhibition of alpha 2-adrenergic vasoconstriction during contraction of glycolytic, not oxidative, rat hindlimb muscle. Am J Physiol (1994) 2.18
Occupational exposure to carcinogens in the European Union. Occup Environ Med (2000) 2.18
The impact of contact with psychiatry on senior medical students' attitudes toward psychiatry. Acta Psychiatr Scand (2007) 2.15
Risk factors for delayed immunization among children in an HMO. Am J Public Health (1994) 2.14
A physical map of 4 million bp around the Duchenne muscular dystrophy gene on the human X-chromosome. Cell (1986) 2.12
Using a birth cohort to study ageing: representativeness and response rates in the National Survey of Health and Development. Eur J Ageing (2013) 2.12
Cleavage site analysis in picornaviral polyproteins: discovering cellular targets by neural networks. Protein Sci (1996) 2.12
Clinically silent microemboli in patients with artificial prosthetic aortic valves are predominantly gaseous and not solid. Stroke (1997) 2.12
Cancer mortality among man-made vitreous fiber production workers. Epidemiology (1997) 2.10
Rhamnose-induced propanediol oxidoreductase in Escherichia coli: purification, properties, and comparison with the fucose-induced enzyme. J Bacteriol (1979) 2.10
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract (2013) 2.09
Protein distance constraints predicted by neural networks and probability density functions. Protein Eng (1997) 2.07
Evolution and utility of a Pseudomonas aeruginosa drug resistance factor. J Bacteriol (1976) 2.06
Cortical-basal ganglionic degeneration. Neurology (1990) 2.04
RNase H activity associated with bacterially expressed reverse transcriptase of human T-cell lymphotropic virus III/lymphadenopathy-associated virus. J Biol Chem (1987) 2.01
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia (2007) 2.01
Eye injuries after nonocular surgery. A study of 60,965 anesthetics from 1988 to 1992. Anesthesiology (1996) 2.00
Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg (1996) 1.99
Beginning readers' use of orthographic analogies in word reading. J Exp Child Psychol (1998) 1.98
A myosin missense mutation, not a null allele, causes familial hypertrophic cardiomyopathy. Circulation (1995) 1.98
Genetic analysis of a chromosomal region containing genes required for assimilation of allantoin nitrogen and linked glyoxylate metabolism in Escherichia coli. J Bacteriol (1999) 1.97
An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J Clin Microbiol (2000) 1.97
Mutation rate varies among alleles at a microsatellite locus: phylogenetic evidence. Proc Natl Acad Sci U S A (1996) 1.96
Time course of vasospasm in man. J Neurosurg (1978) 1.93
An outbreak of Shigella dysenteriae type 2 among laboratory workers due to intentional food contamination. JAMA (1997) 1.93
Prevalence of psychiatric disorders among persons convicted of driving while impaired. Arch Gen Psychiatry (2001) 1.93
Use of highly encapsulated Streptococcus pneumoniae strains in a flow-cytometric assay for assessment of the phagocytic capacity of serotype-specific antibodies. Clin Diagn Lab Immunol (1998) 1.93
Polymorphism of the 5'-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens (1998) 1.93
Body mass index and the risk of obesity in coeliac disease treated with the gluten-free diet. Aliment Pharmacol Ther (2012) 1.89
Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet (2001) 1.88
Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity (1999) 1.88
Demonstration in vitro that eucaryotic initiation factor 3 is active but that a cap-binding protein complex is inactive in poliovirus-infected HeLa cells. J Virol (1984) 1.87
The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med (2001) 1.84